A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

BACKGROUND. Sorafenib has proven survival benefits in patients with advanced hepatocellular carcinoma (HCC). The viability of continuing sorafenib at a higher dosage in patients who experienced radiologic disease progression was investigated. METHODS. Patients who experienced disease progression whi...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Rimassa, Lorenza, Pressiani, Tiziana, Boni, Corrado, Carnaghi, Carlo, Rota Caremoli, Elena, Fagiuoli, Stefano, Foa, Paolo, Salvagni, Stefania, Cortesi, Enrico, Chiara Tronconi, Maria, Personeni, Nicola, Bozzarelli, Silvia, Chiara Banzi, Maria, Fanello, Silvia, Romano Lutman, Fabio, Giordano, Laura, Santoro, Armando
Materialtyp: Artigo
Språk:Inglês
Publicerad: AlphaMed Press 2013
Ämnen:
Clinical Trial Results
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3639524/
https://ncbi.nlm.nih.gov/pubmed/23580239
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0221
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk